Tenax Therapeutics, Inc. (TENX) News
Filter TENX News Items
TENX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest TENX News From Around the Web
Below are the latest news stories about TENAX THERAPEUTICS INC that investors may wish to consider to help them evaluate TENX as an investment opportunity.
Will Tenax Therapeutics (NASDAQ:TENX) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, although... |
Tenax Therapeutics: Q3 Earnings SnapshotCHAPEL HILL, N.C. (AP) — Tenax Therapeutics Inc. TENX) on Wednesday reported a loss of $4 million in its third quarter. On a per-share basis, the Chapel Hill, North Carolina-based company said it had a loss of 19 cents. |
Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateRaised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 52 Investigative Sites Now Initiated Cash Runway Through End of 2027 CHAPEL HILL, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonar |
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation ConferenceCHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will participate in the Guggenheim Healthcare Innovation Conference in Boston, Massachusetts, from November 11-13, 2024. Tenax’s CEO, Chris Giordano, will provide an update on the compa |
TENX: $100 Million Capital RaiseBy John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Tenax Therapeutics, Inc. (NASDAQ:TENX) reported second quarter 2024 results on August 13th, 2024 in a press release and through the filing of its Form 10-Q with the SEC. The big news for Tenax has been the impressive capital raise of $100 million in August 2024. Tenax’ $100 million private placement closed one day before |
Tenax Therapeutics: Q2 Earnings SnapshotCHAPEL HILL, N.C. (AP) — Tenax Therapeutics Inc. TENX) on Tuesday reported a loss of $3.6 million in its second quarter. On a per-share basis, the Chapel Hill, North Carolina-based company said it had a loss of $1.83. |
Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateRaised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 39 Investigative Sites Initiated In April, Hosted the KOL Event, “LEVEL Setting,” Featuring Four Experts in Heart Failure Discussing the Unmet Medical Need in PH-HFpEF and Potential of Levosimendan to Address Disease CHAPEL HILL, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (“Tenax”) (Nasdaq: TENX) |
Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program• Funding supports advancement of oral levosimendan (TNX-103) Phase 3 development program, including completion of the ongoing LEVEL Study for the treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction (PH-HFpEF) • Proceeds also will fund the initiation of a second Phase 3 study planned for 2025, shortening timeline to NDA submission; the protocol for this study will be submitted to FDA for comment CHAPEL HILL, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Tenax Ther |
Tenax Therapeutics Announces Oversubscribed $100 Million Private PlacementCHAPEL HILL, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing that is expected to result in total gross proc |
TENX: First Quarter ResultsBy John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Tenax Therapeutics, Inc. (NASDAQ:TENX) reported first quarter 2024 results on May 14th, 2024 in a press release and the filing of its Form 10-Q with the SEC. Since the beginning of the year, the company has enrolled the first patient in the oral levosimendan (TNX-103) LEVEL trial and presented data at a cardiovascular |